DSGNDesign Therapeutics, Inc.
$11.49+77% 1Y
$11.49
$5.5352 weeks$15.94
DSGN in its own filings
Nothing in DSGN's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
81
Events found in the filings · across 264 filings · the record starts in 2021
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 3, 2026
Most recent filing · Form 10-Q
- Record starts
- Feb 23, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- SEC comment-letter activity12 occurrences
- 2025-05-14
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 18, 2026On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”)Other event · Form 8-K
- Apr 28, 2026Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates.Earnings release · press release
- Apr 1, 2026On March 31, 2026, the Board appointed David Shapiro, M.D., to the Board as a Class III director, effective immediately, with a term ending at the Company’s 2027 annual meeting of stockholders.Director or officer change · Form 8-K
- Mar 9, 2026Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates.Earnings release · press release
- Jan 30, 2026On January 29, 2026, Deepa Prasad notified Design Therapeutics, Inc. (the “Company”) of her decision to resign from the Company’s Board of Directors, effective February 1, 2026, due to required conflict-avoidance policies associated with her newly appointed role with a major bank.Director or officer change · Form 8-K
- Nov 5, 2025Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results.Earnings release · press release
- Sep 10, 2025On September 9, 2025, Arsani William, M.D., tendered his resignation as a member of the board of directors (the “Board”) of Design Therapeutics, Inc. (the “Company”), effective September 9, 2025 (the “Effective Date”), which was not the result of any disagreement with the Company on any matter related to its …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…